A copy of the final prospectus supplement relating to the offering will be filed with the SEC and may be obtained, when available, from Goldman Sachs & Co.
#BLUEPRINT MEDICINE STOCK REGISTRATION#
A preliminary prospectus supplement describing the terms of the offering has been filed with the SEC and forms a part of the effective registration statement. The offering will be made only by means of a prospectus. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. The offering is expected to close on or about January 27, 2020, subject to the satisfaction of customary closing conditions.Ī registration statement on Form S-3 (File No. 333-216573) relating to these securities has been previously filed with the Securities and Exchange Commission ( SEC) and has become effective. are acting as co-lead managers for the offering. Canaccord Genuity LLC, JMP Securities LLC, and Raymond James & Associates, Inc. LLC and Cowen and Company, LLC are acting as joint book-running managers for the offering.
0 kommentar(er)
